NEW YORK, NY / ACCESSWIRE / May 6, 2022 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Vertiv Holdings Co (NYSE:VRT)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/vertiv-holdings-co-loss-submission-form?prid=26915&wire=1
Lead Plaintiff Deadline: May 23, 2022
This lawsuit is on behalf of persons and entities that: (a) purchased or otherwise acquired Vertiv securities between February 24, 2021, and February 23, 2022, inclusive; and/or (b) purchased Vertiv shares in or traceable to the Company's secondary public offering of Class A common stock conducted on or around November 4, 2021.
Allegations against VRT include that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
International Business Machines Corporation (NYSE:IBM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/international-business-machines-corporation-loss-submission-form?prid=26915&wire=1
Lead Plaintiff Deadline: June 6, 2022
Class Period: April 4, 2017 - October 20, 2021
Allegations against IBM include that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/aurinia-pharmaceuticals-inc-loss-submission-form?prid=26915&wire=1
Lead Plaintiff Deadline: June 14, 2022
Class Period: May 7, 2021 - February 25, 2022
Allegations against AUPH include that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong